S.3872 has been around since June 3, 2020... the 116th Congress. It is a Provisional pathway for those that would have been considered under "Right to Try, CSP, etc. essentially covers the ground for those in serious or life-threatening situations with nowhere to go with regard to medical treatment. The Provision can be rescinded... if not activated to market within 6 months. The Act is in our wheelhouse... given the two points of concern..(1) Safety...)2) Efficacy...further, the ACT requires a central registry that reports results for all to view and act accordingly to the benefit of patients. An interesting part of the Act assures that the "experimental" drug manufacturer would not be held liable for its use. The drug must be labeled as provisional...and both private and Federal health agencies cannot Deny coverage. NOW we wait for its implementation...the Hard part.